A phase 3 study for a biosimilar of ranibizumab for neovascular AMD has reported equivalent efficacy and similar safety for 705 nAMD patients.
A team of clinical researchers based at Johns Hopkins Hospital, Baltimore, Maryland, has reported findings of equivalent efficacy and similar safety and immunogenicity profiles with… Read More »A phase 3 study for a biosimilar of ranibizumab for neovascular AMD has reported equivalent efficacy and similar safety for 705 nAMD patients.